Beam Therapeutics had five patents in advanced materials during Q2 2024. Beam Therapeutics Inc filed a patent in Q2 2024 related to compositions, preparations, nanoparticles, and nanomaterials along with methods of their use. GlobalData’s report on Beam Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Beam Therapeutics had no grants in advanced materials as a theme in Q2 2024.
Recent Patents
Application: Nanomaterials comprising an ionizable lipid (Patent ID: US20240115511A1)
The patent filed by Beam Therapeutics Inc. describes compositions, preparations, nanoparticles, and nanomaterials for use in various methods. The compounds described in the patent have specific structural formulas and characteristics, including the presence of certain groups and chains. These compounds can be used in lipid nanoparticle (LNP) preparations for delivering therapeutic agents to subjects in need, treating diseases or disorders, and producing specific polypeptides in mammalian cells. Additionally, the patent covers methods for inhibiting the production of polypeptides, delivering agents to mammalian organs, and specifically targeting therapeutic agents to desired locations within the body.
The patent also includes claims related to the specific structures of the compounds, such as the presence of certain groups like hydrocarbon chains, carbocyclic rings, and heterocyclyl rings. The lipid nanoparticle preparations described in the patent contain ionizable lipids that are essential for delivering therapeutic agents effectively. Furthermore, the patent outlines methods for administering therapeutic agents, treating diseases, inhibiting polypeptide production, and delivering agents to specific organs within mammalian subjects. Overall, the patent provides a comprehensive framework for utilizing specific compounds and lipid nanoparticle preparations in various therapeutic and prophylactic applications, highlighting their potential in targeted drug delivery and disease treatment.
To know more about GlobalData’s detailed insights on Beam Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.